When Chromosomal Abnormalities Are Transmitted to Pregnancy
Chromosomal abnormalities are transmitted to the fetus at the moment of conception, originating either from errors during gametogenesis (egg or sperm formation) or immediately after fertilization during early embryonic cell division.
Timing and Mechanisms of Transmission
Pre-Conception Origins
The majority of chromosomal abnormalities arise during gametogenesis—the formation of eggs or sperm—before conception even occurs 1. This happens through:
- Meiotic errors (non-disjunction) during egg or sperm formation, where chromosomes fail to separate properly
- Maternal age effect: The risk increases significantly with advancing maternal age, particularly for conditions like trisomy 21 (Down syndrome)
- Parental balanced translocations: Parents who carry balanced chromosomal rearrangements can pass unbalanced forms to offspring 2, 3
Post-Fertilization Origins
Chromosomal abnormalities can also develop after fertilization during early embryonic development 4, 1:
- Postzygotic errors occurring during the first cell divisions after conception
- These lead to mosaicism, where some cells have normal chromosomes while others are abnormal 5
- The timing of these errors determines the distribution and severity of the abnormality throughout fetal tissues
Clinical Implications by Gestational Age
First Trimester (10-14 weeks)
Chorionic villus sampling (CVS) can diagnose chromosomal abnormalities from 10-13 weeks' gestation 6. However, a critical caveat: CVS samples placental tissue, which may show confined placental mosaicism (CPM)—chromosomal abnormalities present only in the placenta but not in the fetus 7. When CVS shows mosaicism, follow-up amniocentesis is mandatory because CVS cannot distinguish between CPM and true fetal mosaicism 7.
Second Trimester (15+ weeks)
Amniocentesis can be performed starting at 15 weeks and directly samples fetal cells from amniotic fluid 6. This provides more definitive information about the fetal karyotype compared to CVS, particularly for mosaic conditions 7.
Key Screening vs. Diagnostic Testing Distinction
Screening Tests (Non-Diagnostic)
- Cell-free DNA (cfDNA/NIPT): Detects fetal DNA fragments in maternal blood, primarily screening for trisomies 21,18,13, and sex chromosome abnormalities 8, 9
- First trimester combined screening: Nuchal translucency ultrasound plus maternal serum markers (PAPP-A, hCG) at 11-14 weeks 6
- Important limitation: Screening tests do NOT diagnose—they only assess risk. Positive screens require confirmatory diagnostic testing 7, 8
Diagnostic Tests (Definitive)
- CVS (10-13 weeks) and amniocentesis (15+ weeks) with karyotype or chromosomal microarray are the ONLY definitive diagnostic methods 6, 7, 6
- Chromosomal microarray (CMA) should be included when testing for fetal growth restriction or structural anomalies, as it detects microdeletions/duplications missed by standard karyotype 10
Critical Counseling Points
All Women Should Be Offered Options
Regardless of maternal age, all pregnant women should be offered the choice of diagnostic testing, screening, or no testing after appropriate counseling 6, 8. The decision should respect patient autonomy and preferences.
Abnormalities Not Detected by Standard Screening
Traditional screening and even cfDNA miss approximately 16.9% of all chromosomal abnormalities that would be detected by diagnostic testing 8. Younger women (<25 years) have the lowest detection rates with cfDNA because they have a higher proportion of rare chromosomal abnormalities beyond trisomies 21,18, and 13 8.
When Diagnostic Testing Is Essential
Invasive diagnostic testing should be offered (not just considered) in 10:
- Severely small-for-gestational-age fetuses with structural anomalies
- Non-anomalous fetuses detected before 23 weeks with severe growth restriction
- Any positive screening result requiring confirmation 7
Common Pitfalls to Avoid
- Never treat CVS mosaicism as confirmatory: Always follow up with amniocentesis 7
- Don't rely solely on cfDNA for comprehensive screening: It misses structural rearrangements, many microdeletions, and rare aneuploidies 8
- Don't perform concurrent traditional screening and cfDNA: Choose one first-line approach 8
- Don't skip CMA when indicated: Standard karyotype alone misses 4-10% of clinically significant abnormalities in growth-restricted fetuses 10
The chromosomal abnormality itself is present from conception or very early embryonic development, but our ability to detect it depends on the timing and method of testing chosen during pregnancy.